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Abstract: HIV-1 can be subdivided into distinct subtypes; the consequences of such a genomic variability remain largely 
speculative. The long terminal repeats (LTR) control HIV transcription and reflect the major differences of distinct viral 
subtypes. Three regions in the HIV-1 subtype B LTR are close matches to the Signal Transducer and Activator of Tran-
scription (STAT) consensus sequence. Here, we show heterogeneity in these putative STAT binding sites among HIV-1 
LTR subtypes A through G. Transfection of constitutively activated STAT5 lead to transcriptional activation of HIV-1 
expression in 293T cells transfected with a reporter assay driven by HIV-1 LTR subtype B. Constitutively activated 
STAT5 transactivated the LTR of various subtypes in U937 cells with different potency. These findings support and ex-
pand the potential relevance of STAT5 activation in HIV infection and may bear relevance for a differential regulation of 
latency and expression of different subtypes of HIV-1. 
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INTRODUCTION 
  The human immunodeficiency virus type 1 (HIV-1), the 
etiological agent of acquired immunodeficiency syndrome 
(AIDS), can be classified in 3 distinct groups defined as ma-
jor (M), outlier (O) and new (N). Most HIV-1 isolates identi-
fied to date in the pandemic belong to the group M that has 
spread worldwide within the last 25 years [1]. The other two 
HIV-1 groups are confined to a more restricted geographical 
area in Sub-Saharan Africa whereas several infected indi-
viduals from West-Central Africa harbor viruses from the 
distinct group O. More recently, one member of the third 
group N was isolated from an AIDS patient in Cameroon [2]. 
Group M viruses, responsible for the global pandemic, have 
diversified during their worldwide spreading and have been 
grouped according to their genomic sequences leading to at 
least 10 distinct subtypes (or clades) termed A through K [1, 
3]. These different subtypes are not distributed evenly in that 
subtype B predominates in North America and Europe, 
whereas subtype C prevails in Sub-Saharan Africa [4]. Fur-
ther, more than 20 Circulating Recombinat Forms (CRF) 
have been reported [3]. The relevance of CRFs in the global 
HIV-1 pandemics is increasingly recognized, accounting for 
18% of incident infecion [5, 6] and representing the local 
predominant form in Southeast Asia (CRF01-AE) [7, 8] or in  
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West and West-Central Africa (CRF02-AG) [9, 10]. At pre-
sent, there is no clear-cut evidence for subtype specific varia-
tion in virulence or transmission, and their diverse geo-
graphical distribution is likely to result from stochastic foun-
der effects. Nevertheless, the possibility that the different 
subtypes are heterogeneous in some aspects of their biologi-
cal properties, such as cell tropism and/or regulation of gene 
transcription, which may affect their pathogenic potential, 
cannot be excluded. In this regard, the non-coding HIV-1 
long terminal repeats (LTR), the major transcriptional regu-
lator unit of virus expression, reflect the major differences 
observed among HIV-1 subtypes. For example, both duplica-
tions and diminution of DNA binding sites for the cellular 
transcription factor NF-kB have been described in the case 
of clade C and clade AE (CRF-01-AE), respectively [11-14]. 
  In this scenario, 3 independent regions in the HIV-1 LTR 
subtype B have been recently identified as close matches to 
the signal transducer and activator of transcription 5 
(STAT5) consensus-binding sequence along with functional 
evidence of an upregulatory effect of STAT5 activation on 
viral transcription [15]. STAT5 is a transcription factor trig-
gered by several type I cytokines either belonging to the -
common (c, i.e. interleukin-2, IL-2, IL-7, IL-9, IL-15, IL-
21) or c (IL-3, IL-5 and granulocyte-macrophage colony 
stimulating factor, GM-CSF) families [16, 17]. Thus, STAT5 
represents a key factor transducing the effects of several cy-
tokines and its involvement in the regulation of HIV-1 sub-
type B transcription raises the question about its potential 
role in controlling the expression of other HIV-1 subtypes. STAT5 Transactivates the LTR of Different HIV-1 Subtypes  The Open Virology Journal, 2007, Volume 1    27 
  Therefore, in the present study we analyzed the LTR se-
quences of different HIV-1 subtypes in order to verify the 
presence and potential variability of putative STAT-binding 
sites and investigated their role in the regulation of viral 
transcription. We indeed report the presence of heterogeneity 
in such putative STAT binding sites among the different 
HIV-1 LTR subtypes A through G, including an AG CRF. In 
addition, we provide direct evidence of the inductive role of 
constitutively phosphorylated STAT5 in triggering HIV-1 
LTR subtype B transactivation, in the absence of cytokine 
stimulation. Finally, we demonstrate that constitutively 
phosphorylated STAT5 transactivates HIV-1 LTR subtype A 
through G with different potency. 
MATERIALS AND METHODS 
  Cell lines and reagents. HEK 293T cells were propa-
gated in I-MDM (Bio-Whittaker, Verviers, Belgium) sup-
plemented with 10% FCS (Bio-Wittaker) and penicillin-
streptomycin-glutamine (PSG). The U937 cell line was 
maintained in RPMI 1640 medium (Bio-Whittaker), contain-
ing 10% FCS and PSG. Recombinant granulocyte-
macrophage colony stimulating factor (GM-CSF, R&D Sys-
tems, Minneapolis, MS) was used at 20 ng/ml, based on pre-
vious results [18]. 
  LTR nucleotide sequence analysis. Specific subtypes 
LTR sequence were obtained and characterized as reported 
in Jeeninga et al., 2000 [14]. Briefly, human serum samples 
from patients suspected of having a non-subtype B HIV-1 
infection were selected from the outpatient clinic of the Aca-
demic Medical Center of the University of Amsterdam (Am-
sterdam, The Netherlands), and the LTR-gag region of the 
viral genome was amplified by reverse transcription (RT)-
PCR as described [19]. A detailed comparison of these viral 
sequences with their subtype reference sequences has been 
discussed previously [19]. The 3’ HIV-LTR nucleotide se-
quences of the subtype A through G and G” (CRF-AG) [14] 
were analyzed for the identification of potential transcription 
factor binding sites with two independent softwares: MatIn-
spector Professional (Genomatix Software, Munich, Ger-
many, http://www.genomatix.de/index.html; date of access: 
03-18-05), based on the MatInspector program [20] using the 
selected matrix library (vertebrate section) and optimized 
thresholds, and TFSEARCH (www.rwcp.or.jp/papia; date of 
access: 03-10-05), based on COMPEL databases (www.tra-
nsfac.gbf.de/TRANSFAC or www.bionet.nsc.ru/TRRD). 
  Nucleotide sequence accession numbers. LTR nucleo-
tide sequences from representative subtype clones have been 
deposited in the GenBank database. Their accession numbers 
are: AF127566 (subtype A), AF127567 (subtype C), 
AF127569 (subtype D), AF127570 (subtype E (CRF01-
AE)), AF127571 (subtype F), AF127572 (subtype G), and 
AF127573 (subtype G”(CRF02-AG)). Strain specific se-
quences for intra-subtype heterogeneity analysis were ob-
tained from Los Alamos HIV Database (http://www.hiv. 
lanl.gov/content/hiv-db). 
 Plasmids. The HA-tagged STAT5A c-DNA (kindly do-
nated by B. Mathey-Prevot, Harvard University, Boston, 
MA) was subcloned into the expression vector pXM to gen-
erate the pXM-HA-STAT5A plasmid. The N642H mutation, 
that renders STAT5 constitutively phosphorylated [21, 22], 
was created by PCR mutagenesis as described [18]. The 
pGL2--Casein-luciferase (luc) construct contains 4 tandem 
repeats GAS sequences from the murine casein promoter 
(core sequence: ATTTCTAGGAAATCG) inserted upstream 
of the luc gene in a pGL2 vector (Promega) [23]. The gen-
eration and characterization of the pBlue3’LTR-luc plas-
mids, containing LTR sequence from different subtypes, has 
been previously described [14]. The eGFP-PN lentiviral 
vector was obtained by inserting the eGFP PCR-amplified 
ORF in the ClaI site upstream the PGK-LNGFR selection 
marker cassette in the HIV-1 based lentiviral vector PN 
vector as described [24]. 
  Pseudotyped lentiviral vector production, transduc-
tion,  LNGFR immune selection and LTR-GFP assay. 
VSV-G pseudotyped PN-GFP lentiviral vector stock pro-
duction, the transduction of 293T cells with the correspond-
ing vector, and the following LNGFR immune selection to 
>95% purity, were performed following standardized proce-
dures as reported in [24]. NGFR
+ transduced cells showing a 
constitutive basal GFP expression (NGFR
+/GFP
+) were 
sorted to obtain a highly enriched NGFR
+/GFP
- subpopula-
tion. Cells were then transfected with different amounts of 
pXM or pXM-HA-STAT5A or pXMHA-STAT5A-P (ex-
pressing constitutively activated STAT5A) by Fugene6
® 
according to the manufacturer’s instructions (Roche, Indian-
apolis, IN). For detection of LTR-driven GFP expression, 
cells were acquired by FACScan
® (Becton Dickinson, Frank-
lin Lakes, NJ) and analyzed by CellQuest software (Becton 
Dickinson). 
  Transfection and luc activity assay. U937 cells were 
transfected by the Amaxa electroporator Nucleofector I and 
Nucleofector Kit V (program V-01) according to the manu-
facturer’s procedure (AMAXA Biosystems, Cologne, Ger-
many). In order to evaluate transfection efficiency (estimated 
to be approximately 50%), cells were transfected with the 
pmaxGFP plasmid (AMAXA Biosystems). STAT5-induced 
activation of LTR-luc construct (pBlue3’LTR-Luc) was de-
termined by co-transfection with either pXM, pXM-HA-
STAT5A, or pXM-HA-STAT5A-P. Twenty-four h after 
transfection, cell lysates were mixed with the luciferin sub-
strate (Promega, Madison, WI) and luc activity was meas-
ured by a luminometer (Lumino, Stratec Electronic, Bath, 
UK). STAT5-activated LTR activity was calculated as rela-
tive luc units (RLU)/mg protein of the lysate and expressed 
as fold increase above basal level. 
  Electrophoretic mobility shift assay (EMSA). Whole 
cell extracts (WCE) were prepared as previously described 
[25]. WCE were incubated with different [-
32P]-ATP-end 
labeled double stranded oligonucleotides corresponding to 
the STAT binding consensus sequences (Santa Cruz Bio-
technology, Inc., Santa Cruz, CA) or the STAT-binding se-
quence of HIV-1 subtype G LTR (Fwd 5’- GGA CTT TCC 
GGG AAG CCC CGC C - 3’; Rev 5’- GGC GGG GCT TCC 
CGG AAA GTC C -3’) as described [25]. 
RESULTS 
  Heterogeneous putative STAT DNA binding se-
quences in the LTR of different HIV-1 subtypes. In order 
to investigate the potential role of STAT5 as modulator of 
HIV transcription and virus expression, we have searched for 
putative STAT-binding sites in the HIV-1 LTR by the Ge-
nomatrix software. To this aim we analyzed specific sub-28    The Open Virology Journal, 2007, Volume 1  Crotti et al. 
types LTR sequences previously obtained and characterized 
by Jeeninga et al. 2000 [14]. The subtype A sequence was 
actually obtained from an individual infected with an AC 
CRF with the LTR element derived from subtype A[14]. The 
CRF01-AE is now the more accepted sequence representing 
HIV-1 subtype E with the LTR portion from subtype E since 
no full length E viral isolate has been obtained thus far [7, 8]. 
The subtype G” is a cluster of sequences from AG CRF 
(CRF-IbNG) with the LTR portion that is closely related to 
that of subtype G [26]. 
  We identified a region, located between -77 and -85 in 
the LTR matching to the STAT-consensus binding sequence, 
i.e.: 5’-TTC (N3) GAA-3’, as shown in Fig. (1). This puta-
tive consensus STAT binding site showed different degrees 
of homology in the LTR of subtypes A through G and G” 
(CRF02-AG) (Table 1). 
Table 1.  Genomatrix Analysis of STAT Consensus Sequence 
 
HIV-LTR Subtype  Core Sequence  
Similarity* 
Matrix Sequence  
Similarity** 
A 0.758  0.874 
B 1  0.742 
C 1  0.768 
D 1  0.742 
E (CRF01-AE)  0.758  0.874 
F  Under threshold  Under threshold 
G 1  1 
G” (CRF02-AG)  1  0.761 
*Defined as the consecutive (usually 4) highest conserved positions of the matrix. The 
maximum core similarity of 1.0 is only reached when the highest conserved bases of a 
matrix match exactly in the sequence. **Defined as the entire sequence of the putative 
DNA binding site. A perfect match to the matrix is indicated by a score of 1.0 (each 
sequence position corresponds to the highest conserved nucleotide at that position in 
the matrix), a statistically significant match to the matrix must show a similarity of 
>0.8. 
 
  All the subtypes showed a conserved 5’ sequence TTC, 
whereas several differences were observed both in the length 
of the spacer (N3) region and in the 3’ sequence GAA (Fig. 
1). The canonical 3 nucleotide length of this spacer region 
was conserved only in subtypes C, G and G”(CRF02-AG), 
whereas 4 nucleotides were present in subtypes B and D and 
a longer spacer (5 nucleotides) was observed in subtypes A, 
E (CRF01-AE) and F (Fig. 1). The 3’ sequence GAA was 
conserved only in subtype G in that all the other subtypes 
showed either an A-to-C or an A-to-G substitution at the 
level of the third nucleotide of the 3’ sequence. Finally, an 
additional A-to-G substitution was observed at the level of 
the second nucleotide of the subtype F and G”(CRF02-AG) 
3’ sequence (Fig. 1). Of interest is the fact that the subtype G 
sequence perfectly matched the STAT binding consensus 
sequence. Subtypes B, C and D putative STAT-binding se-
quences LTR contained regions with a similar degree of ho-
mology to the canonical STAT binding consensus sequence, 
whereas a lower score of matching was assigned to the se-
quence present in the LTR of subtype A and E (CRF01-AE). 
Finally, subtype F showed the lowest homology and was 
actually under the threshold of the assay (Table 1). Similar 
results were obtained using TFSearch, an independent bioin-
formatic software analyzing the presence of putative binding 
sites for transcription factors (data not shown). Each of the 
eight subtypes LTR sequences analyzed for the presence of 
STAT binding site was then aligned with strain specific se-
quences from the Los Alamos HIV Database (http://www. 
hiv.lanl.gov/content/hiv-db), in order to evaluate  their het-
erogeneity in this small nucleic acid motif. All subtype pro-
totypical sequences were representative of more than 50% of 
the sequences deposited in the Database, with the exception 
of subtype G (Table 2). In this regard, most (67.8%) of the 
clade G STAT binding sites were identical to the sequence 
found in clade G”(CRF02-AG) (data not shown). The STAT 
binding sequence of the subtype B-LAI virus was indicated 
as a prototypical "B" site in that conserved in >60% of the 
sequences present in the Los Alamos Database and because 
it was previously adopted as reference sequence [15]. These 
findings support and extend the observation that a consensus 
STAT binding element is present in the subtype B HIV-1 
LTR [15]. 
  Constitutively phosphorylated STAT5 triggers sub-
type B HIV-1 LTR activation. Selliah et al. have shown 
that the c-cytokines IL-2 was able to phosphorylate STAT5 
and transactivate the HIV-1 LTR [15]. However, both IL-2 
and other STAT5-activating cytokines are known to activate 
multiple pathways that may influence HIV transcription and 
expression [27]. Therefore, we next investigated whether 
STAT5 phosphorylation per se could directly lead to LTR 
transactivation by use of different STAT5 expression vec-
tors. In particular, a reporter plasmid carrying the firefly lu-
ciferase gene under the control of the -casein promoter was 
transfected in 293T cells together with the pXM vector ex-
pressing either a constitutively phosphorylated isoform of   
 
 
Fig. (1). STAT putative binding site are present in the LTR of different HIV-1 subtypes. Alignment of the HIV 3’LTR sequences of 
subtype A through G and G”: putative STAT DNA binding sites are boxed. Underlined are NF-B and Sp1 binding sites. Reference STAT5 
binding consensus sequence: TTC (N3) GAA [46]. STAT5 Transactivates the LTR of Different HIV-1 Subtypes  The Open Virology Journal, 2007, Volume 1    29 








quences/Total  % 
A TTTCCAGGGGAG 24/39 61.5 
B TTTCCAGG_GAG 35/54  64.8 
C GTTCCAG__GAG  46/75  61.3 
D TTTCCAG_GGAG 21/40  52.5 
E (CRF01-AE)  TTTCCAGGGGAG 29/30 96.6 
F TTTCCAGAGGGC 5/9 55.5 
G TTTCC__GGGAA 1/28 3.5 
G” 
(CRF02-AG) 
TTTCC_GGGGAG 14/19  73.6 
 
STAT5 (pXM-HA-STAT5-P) or a conventional, unphos-
phorylated STAT5 (pXM-HA-STAT5A); the pXM empty 
vector alone was also included as control. These vectors 
were tested for their capacity to induce transcription of a 
STAT5 physiological target such as the -casein promoter 
[23]. As predicted, STAT5-P, but not STAT5 or transfection 
of the empty vector, transactivated the -casein promoter 
(Fig.  2A). Next, we investigated whether STAT5-P could 
modulate transcription directed by the subtype B HIV-1 
LTR. 293T-LTR-GFP cells, carrying a stably integrated 
HIV-based lentiviral vector, expressing GFP under the con-
trol of the 5’ LTR, were transfected with an expression 
plasmid containing either STAT5-P or STAT5. STAT5-P, 
but not STAT5, increased the level of GFP
+ cells in a con-
centration-dependent manner, as detected 48 h after transfec-
tion (Fig. 2B). This effect was reproduced in promonocytic 
U937 cells transiently co-transfected with an HIV-LTR-luc 
reporter gene (Fig. 3A). Overall, our findings confirm and 
extend those of Selliah et al. [15] in primary CD4
+ T cells 
indicating that activation of STAT5 per se can trigger HIV 
transcription in different cell types. 
  Constitutively phosphorylated STAT5 transactivates 
the LTR of HIV-1 subtypes A through G in U937 cells 
with different potency. U937 cells were transfected with 
vectors expressing the luc reporter gene under the control of 
LTR sequences of HIV-1 subtypes A through G together 
with an expression vector carrying the STAT5-P gene or 
with an empty vector as control. STAT5-P transactivated the 
LTR of all different subtypes, except F, although with differ-
ent potency. The highest transactivation capacity was ob-
served in the presence of the subtype G LTR (Fig. 3B), con-
taining a perfect STAT binding site (Table 1). Of interest is 
the fact that no STAT5-P mediated transactivation was ob-
served on the subtype F LTR characterized by the lowest 
matching score for STAT consensus binding sites (Table 1). 
  GM-CSF promotes STAT5 binding to the subtype G 
HIV-1 LTR in U937 cells. In order to confirm that physio-
logical activation of STAT5 could lead to specific DNA 
binding to HIV LTR sequences, we stimulated U937 cells 
with the c-cytokine GM-CSF for 15 min. WCE from either 
unstimulated or GM-CSF stimulated U937 cells were   
 
 
Fig. (2). STAT5–P, but not STAT5, activates the subtype B 
HIV-1 LTR. 293T cells were co-transfected with equal amounts of 
a  -casein responsive firefly luc reporter construct (upper panel) 
and either an empty vector or vectors expressing STAT5 or 
STAT5-P. Similar constructs were transfected in 293T-LTR-GFP 
cells (see Material & Methods). The results represent the mean ± 
SEM of 3 independent experiments. 
incubated with radiolabeled oligonucleotides corresponding 
to either a STAT5 consensus probe, to the regions 
corresponding to either the HIV-LTR STAT consensus 
sequence of subtype G. A DNA-binding complex was 
readily observed by EMSA with WCE from GM-CSF 
stimulated U937 incubated with the subtype G STAT 
consensus sequence probe (Fig. 4, lane 3). This complex was 
specific in that it was competed with a 100-fold excess of 
unlabeled subtype G STAT consensus probe (Fig. 4, lane 4). 
DISCUSSION 
  In the present study, we have analyzed the LTR promoter 
regions of HIV-1 subtypes A through G and G”(CRF02-AG) 
for their potential capacity to bind STAT5, a transcription 
factor induced by cell stimulation with several c- and c-
cytokines. We observed heterogeneity in these putative 
STAT-binding sites among different subtypes with one se-
quence from subtype G perfectly matching the STAT bind-
ing consensus sequence. Other subtype G as well as B, C and  
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Fig. (3). STAT5-P transactivates the HIV-1 LTR from subtypes 
A through G in U937 cells with different potency. A. U937 cells 
were co-transfected with HIV-1 LTR subtype B responsive firefly 
luc and vectors expressing either STAT5 or STAT5-P or an empty 
vector. The results are mean ± SEM of 3 independent experiments. 
B. U937 cells were co-transfected with vectors expressing the fire-
fly luc under the control of HIV-1 LTR of subtypes A through G 
and either empty vector or STAT5-P. The luc activity of different 
HIV-1 LTR subtypes in the presence of vectors expressing either 
STAT5-P or control empty vector (to which the arbitrary value of 1 
was assigned) is shown as fold increase. The results are mean ± 
SEM of 2 independent experiments. 
D putative STAT-binding sequences showed a significant 
similarity with a canonical STAT binding consensus site 
whereas subtype A, E and F did not predict a STAT-binding 
site. STAT5 binding to the perfectly matching subtype G 
sequence was associated with a higher transactivation capac-
ity of a constitutively phosphorylated STAT5 (STAT5-P) in 
U937 cells. In addition to U937 cells, STAT5-P transacti-
vated the subtype B HIV-LTR in stably transfected 293T 
cells. 
  The presence of 3 different STAT-consensus elements 
(named S1, S2 and S3) in the subtype B LTR of NL4-3 was 
previously reported by independent investigators [15]. In 
addition, we have recently confirmed the presence of S2 and 
S3 located in positions -137 to -130 and -85 to -77, respec-
tively [18]. In particular, the STAT binding consensus se-
quence of the HIV-1 LTR of subtype B here described   
 
 
Fig. (4). GM-CSF activates STAT5 binding to the HIV-1 LTR 
subtype G in U937 cells. WCE from either unstimulated or GM-
CSF stimulated U937 cells were incubated with radiolabeled oli-
gonucleotides. A 100-fold excess of unlabeled LTR-subtype G was 
added in lane 4. 
coincides with the S3 sequence reported by Selliah et al. 
[15], whereas the S2 site, located at -137 to -130, is present 
only in the subtype B LTR and was not detected in others 
subtypes by both the bioinformatics softwares used in this 
study. Selliah et al. provided the first evidence that cytokine-
mediated activation of STAT5 [28] could lead to increased 
HIV transcription and viral expression [15]. However, cyto-
kine stimulation can also trigger different pathways leading 
to increased HIV transcription, including NF-B and MAP-
kinase activation [29-31], as reviewed [27]. In particular, 
both IL-6 and GM-CSF stimulation of U1 cell lead to activa-
tion of estrogen-receptor kinase-1/-2 (ERK-1/-2) turning on 
Jun/Fos (AP-1) [32, 33], a transcription factor previously 
linked to the activation of HIV transcription [34-38]. Here, 
we provide direct evidence that activated STAT5 per se, 
independently of c- or c-cytokine stimulation or the activa-
tion of parallel signaling pathways, leads to LTR transactiva-
tion. In addition, we demonstrate that constitutively phos-
phorylated STAT5 transactivates the LTR of the different 
subtypes with different potency, with the highest levels ob-
served with the subtype G LTR containing a canonical 
STAT binding consensus sequence as demonstrated by 
EMSA. The presence of 2 putative STAT-binding site in the 
LTR of subtype B [18] may support the observation that 
higher levels of transactivation were observed in comparison 
to cells transfected with LTR of subtypes C and D, showing 
matching scores similar to that of subtype B. Finally, consti-
tutively activated STAT5 did not transactivate the LTR of 
subtype F that showed the lowest matching score for STAT 
consensus binding site. 
  The increasing prevalence of HIV-1 transmission through 
heterosexual contacts and the growing number of immigrants 
from non-Western countries, where non-B subtypes and re-
combinant forms are prevalent, suggest the possible emer-
gence in Europe of a new epidemic wave of HIV-1 non-B 
subtypes as well as recombinant forms [3]. Three A-family 
subtype and two into the G subtype have been reported in 
Italy [39, 40]. The 5 non-B-subtype HIV-1 isolates have 
been identified among 23 variants (prevalence, 21.74%) iso-
lated during the 2000 to 2001 period in heterosexuals [39]. 
More recently, Camacho and colleagues reported that the 
commonest subtypes in portugal is B (41.7%), but the sub-
type G account for 29.4%, while other non-B subtypes rated STAT5 Transactivates the LTR of Different HIV-1 Subtypes  The Open Virology Journal, 2007, Volume 1    31 
12.8% and recombinant forms represented 16.1% of the 
samples [41]. In this context, the heterogeneity in STAT 
binding site could be relevant for an increasing fraction of 
HIV infected individuals worldwide. 
  STAT5 is a key transcription factor activated by several 
cytokines [16, 17] and it is a critical component of the IL-2 
receptor-mediated signal for CD4
+ T cell proliferation and 
activation [42]. Therefore, the observation of its differential 
effect on the transcription of different subtypes could be 
relevant in term of pathogenicity. In addition, several other 
c-cytokines activating STAT5, including IL-2, IL-7, and IL-
15, have been implicated as regulators of HIV replication 
[43, 44]. Our results expand the observation of a positive 
effect of STAT5 activation on subtype B viral transcription 
[15] to clades A through G. In this regard, we have recently 
reported that a constitutively activated, C-terminus truncated 
STAT5 isoform (STAT5) is frequently detected in leuko-
cytes of HIV
+ individuals and provided direct evidence that 
this post-translationally modified STAT plays a suppressive 
rather than an inductive role on viral transcription and virus 
expression [18]. However, no information is available on 
whether individuals infected with HIV-1 subtypes other than 
B show a similar “aberrant” profile of constitutive STAT5 
activation. 
  In conclusion, heterogeneity of STAT5 binding sequence 
is a novel element distinguishing different HIV-1 subtypes. 
Although there is no evidence at present for subtype specific 
variation in virulence or transmission our findings support 
the possibility that sequence differences among the subtypes, 
at least in the LTR region, can result in diverse biological 
properties and pathogenic potential [11, 12, 45]. 
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